Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLY-220
- Development stage
- Preclinical
- Lead developer
- Glycadia
- Modality
- Small Molecules
01
Overview
GLY-220 is a small molecule drug candidate currently in preclinical development by Glycadia Pharmaceuticals for the treatment of diabetic macrovascular disease and Alzheimer's disease. The compound functions as a glycation inhibitor, specifically targeting the nonenzymatic glycation of proteins. This biochemical process is significantly accelerated in diabetic patients due to chronic hyperglycemia, resulting in the accumulation of glucose-modified proteins and advanced glycation end products (AGEs) that cause vascular damage and contribute to the neurodegenerative pathology observed in Alzheimer's disease. By inhibiting this process, GLY-220 aims to mitigate the progression of diabetic complications and cognitive decline.
Beyond the preview
Go deeper on GLY-220.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLY-220.